Pharmacology Review Questions on Drug Mechanisms and Interactions
This is a pharmacology review spanning principles, cardiovascular, hematology, and nervous-system drug topics: pharmacokinetic concepts (bioavailability as the fraction of a dose reaching systemic circulation; Michaelis-Menten constant (Km) as inverse measure of enzyme-substrate affinity; the three phases of drug metabolism — cytochrome P450 oxidation, phase 2 conjugation, and phase 3 transport-mediated excretion via P-glycoprotein/MDR1); and pharmacodynamic mechanisms of specific drug classes, including funny-channel (If) inhibition, antiarrhythmic potassium interactions, irreversible cyclooxygenase inhibition by aspirin, direct thrombin inhibition, vitamin K epoxide reductase inhibition by warfarin (and its transient procoagulant effect via protein C/S depletion), first-line treatment of absence seizures, tricyclic antidepressant receptor-blockade side-effect profiles, and benzodiazepine/barbiturate binding sites on the GABA receptor. The unifying domain is clinical pharmacology, connecting drug kinetics (absorption, metabolism, elimination) to receptor- and enzyme-level mechanisms that determine therapeutic and adverse effects.